University of Modena and Reggio Emilia
Archivio istituzionale della ricerca - Università di Modena e Reggio EmiliaNot a member yet
116400 research outputs found
Sort by
Juan Andrés e l'uso antiphilosophique della Scienza moderna
No full textIl saggio analizza l'uso polemico della Scienza moderna effettuato dal gesuita spagnolo Juan Andrés. In alcuni suoi saggi apparso alla fine del XVIII secolo, il religioso iberico utilizza la figura di G. Galileo per polemizzare con l'illuminismo francese, in particolare con D. Diderot
L'approccio progettuale nei servizi per l'infanzia del Comune di Parma. Bambini e adulti in ricerca nel sistema integrato 0-6
No full textL’istituzione del sistema educativo integrato 0-6 ha sollecitato anche nelle realtà locali il superamento delle divisioni nell’organizzazione e nel coordinamento pedagogico dei servizi. Nel Comune di Parma l’intento di costruire un coordinamento pedagogico 0-6, a partire da storie diverse che hanno caratterizzano negli anni i nidi e le scuole dell’infanzia, ha portato alla scelta di sviluppare un percorso formativo partecipato che consentisse di confrontarsi sull’impostazione pedagogica e sulle modalità di lavoro nei servizi. La scelta è stata quella di lavorare sull’approccio progettuale, cioè un approccio che valorizza la soggettività e l’impegno immaginativo dei bambini con i problemi, incoraggiando e sostenendo il loro coinvolgimento attivo in processi di esplorazione e scoperta. Un percorso che ha messo in gioco le diverse storie dei servizi e le biografie educative di chi opera nei vari contesti, attivando sperimentazioni di pratiche e riflessioni sulla relazione educativa, sul significato dei processi legati allo sviluppo della progettazione e sul ruolo della coordinatrice pedagogica a supporto dei gruppi. Il volume restituisce gli esiti di tale percorso approfondendo le caratteristiche dell’approccio progettuale e quindi analizzando gli strumenti e i passaggi del processo di ricerca-azione in cui si declina e si sviluppa un itinerario progettuale
Choosing the Hard Way: Being Creative in the Age of Generative AI
No full textAs Generative AI tools con produce content, research is examining the impact of this technology on creativity, with a focus on creative outputs. However, how creativity itself is going to be impacted by this new technological environment is yet to be investigated. Supported by a qualitative enquiry and literature about everyday creativity and AI usage, we explore: a) why people engage in creative activities; b) how those motivations may be impacted by GenAI; c) how people that engage in creative activities perceive GenAI. The results of this work have implications for research, policy makers and companies interested in the promotion of creative activities
Queering Nigerian Literature: Blurring Gender Lines in Akwaeke Emezi’s The Death of Vivek Oji
No full textComplications Following Early Thoracic Endovascular Aortic Repair for Type B Aortic Dissection: A Pathophysiological Deepening
No full textOptimization of ALPPS stage II timing with the APRI/ALBI score-an international, multicenter cohort study
No full textBackground: Primarily unresectable liver tumors may be approached by the Associating Liver Partition and Portal vein Ligation for Staged Hepatectomy (ALPPS) procedure. Post-hepatectomy liver failure (PHLF) poses the most significant risk factor for poor outcomes. The AST-to-platelets ratio index (APRI)/albuminto-bilirubin index (ALBI) score has been proposed as an easy and routinely available score to monitor liver function. Here, we explored the predictive capability of the APRI/ALBI score to determine PHLF and perioperative morbidity to help determine the optimal timing of the 2nd stage of ALPPS. Methods: Based on the international multicenter ALPPS registry, patients from 2012 to 2020 with an available APRI/ALBI score were included. Postoperative outcomes (clinically relevant PHLF B + C, 90-day mortality, and severe morbidity (>= Clavien-Dindo 3b) after ALPPS stage II were assessed. The APRI/ALBI score was monitored perioperatively, and the predictive value was evaluated using logistic regression and receiver operating characteristics. Performance of APRI/ALBI score was compared to the ALPPS futility risk score in this cohort study. Results: Overall, 464 patients from 16 participating centers were included. Clinically relevant PHLF (B + C) was observed in 7.5% of patients, of which 63% ultimately died. After stage I, the APRI/ALBI score gradually recovered. The pre-stage II APRI/ALBI score significantly predicted clinically relevant PHLF [area under the curve (AUC) =0.78; P<0.001], 90-day mortality (AUC =0.67; P=0.002), and severe morbidity (AUC =0.65; P<0.001). Three clinically relevant APRI/ALBI score risk groups were defined: clinically relevant PHLF occurred in 3.1% in the low-, 8.7% in the intermediate-, and 28.0% in the high-risk groups. 90-day mortality was 6.8% in the low-, 15.9% in the intermediate-, and 19.4% in the high-risk groups. Integrated assessment of the established futility risk score in combination with the APRI/ALBI score documented further increased predictive potential for clinically relevant PHLF (AUC 0.81; P<0.001). Conclusions: The APRI/ALBI score allows for simple and dynamic liver function recovery monitoring after the first ALPPS stage. Inadequate recovery of the APRI/ALBI score until ALPPS stage II was associated with PHLF B + C, 90-day mortality, and severe morbidity. With the proposed risk model, optimized timing of the second stage of ALPPS may further increase the safety of this procedure
Mortality using raltegravir versus other integrase strand-transfer inhibitors in people with HIV in Europe and Australia: a prospective multicentre study
No full textBackground: Integrase strand-transfer inhibitors (INSTI) are a key part of contemporary antiretroviral therapy (ART). Raltegravir (RAL) was the first INSTI and remains recommended for some people with HIV. We investigated all-cause mortality between RAL-based ART and other INSTIs in the RESPOND cohort consortium among both ART-naïve and treatment experienced individuals. Methods: RESPOND, a multicenter prospective cohort study, includes approximately 40,000 adults (≥18 years) with HIV from 17 cohorts across Europe and Australia. Individuals eligible for inclusion into RESPOND had ≥1 clinical visit at a site participating in RESPOND after January 01, 2012, and a CD4 count and HIV viral load measurement available at inclusion. Participants in RESPOND who started their first INSTI between JAN 01, 2012 and DEC 31, 2021 were included. All-cause mortality among those starting RAL was compared to those starting any other INSTI using Cox proportional hazards regressions: one model adjusting for age and another weighted by inverse probability of treatment weights (IPTW). Predictors of starting RAL were estimated by logistic regression. Findings: Among 20,349 participants starting an INSTI (15,429 (75.8%) male, 4879 (24.0%) female, and 41 (0.2%) transgender), 938 (4.6%) died during 94,677 person-years of follow-up (PYFU). Crude mortality rates (MR) were higher for participants starting RAL (MR 12.9 per 1000 PYFU; 95% CI 11.5–14.5) than other INSTIs (MR 9.1 per 1000 PYFU; 95% CI 8.4, 9.8). Starting RAL was significantly associated with higher mortality when controlling for age (adjusted hazard ratio (aHR) 1.43; 95% CI 1.25, 1.65). However, after applying IPTW, there was insufficient evidence for a difference in mortality in the full cohort (hazard ratio (HR) 1.13; 95% CI 0.93, 1.34) or among ART-naïve participants (HR 1.23; 95% CI 0.71, 2.12). Starting RAL was associated with higher HIV viral load, hepatitis C positive status (aOR 2.07; 95% CI 1.82, 2.37), prevalent end-stage renal disease (aOR 2.58; 95% CI 1.58, 4.19), chemotherapy near baseline (aOR 1.58; 1.01, 2.48), and cardiovascular disease (aOR 1.58; 95% CI 1.30, 1.91). Interpretation: In this large and well-characterised cohort we found no evidence of an association between all-cause mortality and use of RAL compared to other INSTIs after accounting for confounding at the time of starting the INSTI. Our findings suggest that prior reports of such an association could have been confounded by indication and channelling bias. While a large number of potential confounders were accounted for, the results presented are an estimation of average treatment effect using IPTW which is still vulnerable to uncontrolled confounding. Funding: CHU St Pierre Brussels HIV Cohort, Austrian HIV Cohort Study, Australian HIV Observational Database, AIDS Therapy Evaluation in the Netherlands National Observational HIV cohort, EuroSIDA cohort, Frankfurt HIV Cohort Study, Georgian National AIDS Health Information System, Nice HIV Cohort, ICONA Foundation, Modena HIV Cohort, PISCIS Cohort Study, Swiss HIV Cohort Study, Swedish InfCare HIV Cohort, Royal Free HIV Cohort Study, San Raffaele Scientific Institute, University Hospital Bonn HIV Cohort, University of Cologne HIV Cohort, Brighton HIV Cohort, and the National Croatian HIV cohort, ViiV Healthcare, Merck Life Sciences, Gilead Sciences, and the Centre of Excellence for Health, Immunity Infections (CHIP)
